Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
30 Dezembro 2022 - 10:30AM
Sema4 (Nasdaq: SMFR), a health insights company, today announced
the company will participate in the 41st Annual J.P. Morgan
Healthcare Conference in San Francisco. Katherine Stueland,
President and Chief Executive Officer, will deliver a formal
presentation on Thursday, January 12, 2023, at 10:30 a.m. PT.
A live and archived webcast of the presentation
will be available on the “Events” section of the Sema4|GeneDx
investor relations website at https://ir.sema4.com/.
About Sema4|GeneDx
Sema4|GeneDx is a patient-centered health
intelligence company dedicated to advancing healthcare through
data-driven insights. Sema4 is transforming healthcare by applying
AI and machine learning to multidimensional, longitudinal clinical
and genomic data to build dynamic models of human health and
defining optimal, individualized health trajectories. Centrellis®,
our innovative health intelligence platform, is enabling us to
generate a more complete understanding of disease and wellness and
to provide science-driven solutions to the most pressing medical
needs. Sema4 believes that patients should be treated as partners,
and that data should be shared for the benefit of all.
For more information, please visit sema4.com and connect
with Sema4 on Twitter, LinkedIn,
Facebook and YouTube.
Contact:Tricia TruehartInvestor
Relationsinvestors@sema4.com
Sema4 (NASDAQ:SMFR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sema4 (NASDAQ:SMFR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Sema4 Holdings Corporation da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de